We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Suppression of a Specific Kinase Blocks Growth of Dependent Tumors

By LabMedica International staff writers
Posted on 20 Dec 2018
Print article
Image: A model of the active site of the kinase GSK-3 (glycogen synthase kinase 3) (Photo courtesy of Wikimedia Commons).
Image: A model of the active site of the kinase GSK-3 (glycogen synthase kinase 3) (Photo courtesy of Wikimedia Commons).
A recent paper revealed that the enzyme glycogen synthase kinase 3 (GSK3) was required for the in vitro and in vivo growth and survival of human mutant KRas-dependent tumors but was dispensable for mutant KRas-independent tumors.

Approximately 20% of all human cancers have mutations in the KRas (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene. These KRas-mutant cancers are among the most difficult to treat due to their resistance to chemotherapy.

Since targeting KRas directly has proven difficult, identifying vulnerabilities specific for mutant KRas tumors is an important alternative approach. Toward this end, investigators at the Moffit Cancer Center (Tampa, FL, USA) sought to identify kinases and their corresponding pathways that were required by mutant KRas tumors in order to induce malignant transformation and to target such pathways for cancer therapy.

They reported in the December 4, 2018, online edition of the journal Nature Communications that the kinase GSK3 was necessary for survival of a KRas-dependent cancer cell line, and that suppression of GSK3 inhibited tumor growth by increasing the levels of beta-catenin, a dual function protein, involved in regulation and coordination of cell–cell adhesion and gene transcription, and c-Myc, a regulator of genes and proto-oncogenes that code for transcription factors. Inhibiting phosphorylation of the GSK3 substrates c-Myc and beta-catenin and their subsequent upregulation contributed to the antitumor activity of GSK3 inhibition.

The investigators showed that GSK3 chemical or genetic blockade inhibited the growth in mice of mutant KRas primary and metastatic patient-derived xenografts from pancreatic cancer patients who had progressed despite chemo- and radiation therapies. This discovery has opened new avenues to target mutant KRas-dependent cancers.

“This study discovered a novel vulnerability in mutant KRas-addicted human cancers. We have uncovered an essential link between GSK3 activity and mutant KRas dependency that is highly relevant in many aggressive and end-stage cancers. This discovery opens new avenues to target mutant KRas-addicted cancers,” said senior author Dr. Said Sebti, a senior member of the drug discovery department at Moffit Cancer Center.

Related Links:
Moffit Cancer Center

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Urine Drug Test
Instant-view Methadone Urine Drug Test
New
UHF RFID Tag and Inlay
AD-321r6/AD-321r6-P

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more